

SHARE BUYBACK PROGRAM NOVOZYMES A/S B SHARES

August 31, 2012

On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.

Under the program Novozymes will buy back B shares for an amount of up to DKK 1,000 million in the period from January 20, 2012, to December 31, 2012.

The following transactions have been made under the program:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	4,102,307		645,858,682
August 24, 2012	25,000	162.94	4,073,496
August 27, 2012	20,000	162.95	3,258,991
August 28, 2012	34,000	161.02	5,474,644
August 29, 2012	8,065	163.52	1,318,802
August 30, 2012	20,000	164.78	3,295,658
Accumulated under the program	4,209,372		663,280,273

Transactions related to Novozymes' incentive programs have resulted in a net sale by Novozymes of 49,480 B shares in the period from August 24, to August 30, 2012. The shares related to these transactions were not part of the Safe Harbour share buyback program.

With the transactions stated above, Novozymes owns a total of 11,951,244 treasury shares, corresponding to 3.7% of the share capital. The total amount of shares in the company is 325,000,000 including treasury shares.

Contact persons:

Press and media:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Investor relations:

Maarit Pokkinen

Tlf. (direkte): +45 4446 8682

Tlf. (mobil): +45 3077 8682

Martin Riise

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.